Board Members

• Joseph Leyba, RPh, President
• Lorri Walmsley RPh, Vice President
• Cedar Lahann, PharmD, RPh, Member
• Ted Tong, PharmD, RPh, Member
• Kevin Dang, PharmD, RPh, Member
• Mohammad (Mo) Salari, RPh, Member
• Kristen Snair, CPhT, Member
• Reuben Minkus, Member (Public)

The Board Is on Facebook

Follow the Arizona State Board of Pharmacy for the latest news and updates at https://www.facebook.com/Arizona-State-Board-of-Pharmacy-396869467321193.

Update Your Profile

In an effort to communicate more effectively with its licensees and permittees, the Board noticed that contact information in its system is not always current and up to date. You are required to update your personal contact information and pharmacy employer within 10 days after a change pursuant to Arizona Revised Statutes (A.R.S.) §32-1926. Please use your online profile to update your contact information.

Be on Alert – Scam

You may receive a call from someone impersonating a Board staff member requesting your personal information as well as attempting to obtain payment via credit card over the phone. Please know that the Board has your information, which you are able to update using the Board website anytime. The Board also does not collect payment over the phone. If you experience this activity, please contact the Board office at 602/771-2727.
License Processing Time

The Board continues to receive applications that are incomplete.

The two main items missing include:

1. Fingerprint clearance cards (sample of card below). Prior to applying with the Board, please have your fingerprint clearance card ready to upload with your application. Submitting your Board application and then submitting your fingerprint clearance card at a different time will delay your application from being processed.

![Fingerprint Clearance Card](image)

2. Proof of authorized presence in the United States under federal law (See A.R.S. §41-1080). For example, a driver’s license, a non-operator ID issued by a state located in the US, or other documentation that verifies lawful presence. The following states do not verify lawful presence when issuing a driver’s license or a non-operator ID: California, Colorado, Connecticut, Delaware, District of Columbia, Hawaii, Illinois, Maryland, Nevada, New Jersey, New Mexico, New York, Oregon, Utah, Vermont, and Washington. If your driver’s license is from a state listed above, you will have to submit another form of identification showing lawful presence in the US.

If you have encountered legal issues and were charged, regardless of the outcome, you must provide a police report and court records, if applicable.

For pharmacist application: The Board has been authorized to release your test for your examination(s) prior to the Board reviewing your application. When you pass the examination(s), your license will be issued only after your application and all the supportive documents have been provided and appropriately reviewed. If your application is incomplete, or your appearance is needed before the Board, your license will not be issued until those matters are resolved and Board staff has approval to issue your license. Board staff is encouraged that this new process will speed up the licensing process by several weeks.

Ebola Vaccine

Food and Drug Administration has approved Ervebo®, a live recombinant viral vaccine consisting of a vesicular stomatitis virus (VSV) backbone deleted for the VSV envelope glycoprotein and substituted with the envelope glycoprotein of the Zaire ebolavirus (Kikwit 1995 strain).

Centers for Disease Control and Prevention has given guidance as to the use of this vaccine in case a person with Ebola virus infection was identified in the US.
Ervebo would be indicated as a pre-exposure vaccination for adults 18 years of age and older in the US who are at highest risk for potential occupational exposure to EBOV because they are responding to an outbreak of Ebola virus disease, working as health care personnel at federally designated Ebola treatment centers in the US, or working as laboratorians or other staff at biosafety level 4 facilities in the US.

Although Ervebo is now licensed, the Arizona Department of Health Services (ADHS) has not yet decided whether to add this to Arizona Administrative Code §9-6-1301.

**Antivirals Available for Use in Arizona With Tiered Approach**

The following alert was issued by the Arizona Health Alert Network:

Coronavirus disease 2019 (COVID-19) infections are at record levels across Arizona, and the state’s health care systems are being severely affected. Arizona now has access to therapies that can decrease severity of disease in the most vulnerable patients and help them avoid hospitalization or death due to severe COVID-19. Oral antivirals are available at select pharmacies across the state by prescription only. Please note availability of these antiviral products may vary at each location.

ADHS convened the Arizona Vaccine and Antiviral Prioritization Advisory Committee (VAPAC). VAPAC has approved the strong recommendation that health care professionals utilize tiered prioritization for the use of Paxlovid™ (nirmatrelvir/ritonavir) and molnupiravir in patients meeting the following Tier 1 criteria due to extremely limited supply statewide.

Tier 1 eligible patients include:

- Patients 70 years of age or older; or
- who have major immune suppression (ie, HIV, severe primary immunodeficiency, cancer and/or transplant patients, or patients on chronic steroids or other immunosuppressive drugs)

Full prioritization criteria and a pharmacy locator map may be found in English at Azhealth.gov/antivirals or in Spanish at Azhealth.gov/antivirales.

Eligible patients should be started on these antivirals as soon as possible after confirmed diagnosis of COVID-19 and within five days of symptom onset.

Prescribers should ensure patient eligibility as outlined in the Emergency Use Authorization and health care provider fact sheets prior to writing the prescription. Please note that there are many clinical considerations including potential drug interactions, reproductive concerns, and dose adjustments associated with these therapies.
Health care providers and patients can call 211 or the Arizona Poison Control System COVID-19 Hotline at 844/542-8201 for locations of pharmacies carrying the medications nearest them, or visit the ADHS Antivirals for COVID-19 website and map for treatment locations.

For additional questions, email the ADHS COVID-19 Therapeutics Team at therapies@azdhs.gov.

**Disciplinary Actions and Updates – Health Boards**

Disciplinary actions for the Arizona State Board of Pharmacy, Arizona Medical Board, Arizona Naturopathic Physicians Medical Board, Arizona Board of Osteopathic Examiners, and Arizona Regulatory Board of Physician Assistants can be found at https://pharmacy.az.gov/resources/disciplinary-actions/quarterly-updates.

---

**National Pharmacy Compliance News Now Available!**

Visit NABP’s website for the latest regulatory updates and news from FDA, USP, NABP, and more.

**Read National News**

---

The Arizona State Board of Pharmacy News is published by the Arizona State Board of Pharmacy and the National Association of Boards of Pharmacy Foundation® (NABPF®) to promote compliance of pharmacy and drug law. The opinions and views expressed in this publication do not necessarily reflect the official views, opinions, or policies of NABPF or the Board unless expressly so stated.

Kamlesh “Kam” Gandhi, PharmD - State News Editor

Lemrey “Al” Carter, PharmD, MS, RPh - National News Editor & Executive Editor

Amy Sanchez - Publications and Editorial Manager

**1616 W Adams St, Suite 120 | Phoenix, AZ 85007 | https://pharmacy.az.gov | kgandhi@azpharmacy.gov**